BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35373443)

  • 1. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
    Lane JA; Donovan JL; Young GJ; Davis M; Walsh EI; Avery KNL; Blazeby JM; Mason MD; Martin RM; Peters TJ; Turner EL; Wade J; Bollina P; Catto JWF; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Neal DE; Hamdy FC; Metcalfe C;
    BJU Int; 2022 Sep; 130(3):370-380. PubMed ID: 35373443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
    Chen RC; Basak R; Meyer AM; Kuo TM; Carpenter WR; Agans RP; Broughman JR; Reeve BB; Nielsen ME; Usinger DS; Spearman KC; Walden S; Kaleel D; Anderson M; Stürmer T; Godley PA
    JAMA; 2017 Mar; 317(11):1141-1150. PubMed ID: 28324092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
    Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
    Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
    Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
    JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
    De B; Pasalic D; Barocas DA; Wallis CJD; Huang LC; Zhao Z; Koyama T; Tang C; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    J Urol; 2022 Dec; 208(6):1226-1239. PubMed ID: 36006050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Outcomes After Localized Prostate Cancer Treatment.
    Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
    JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Donovan JL; Hamdy FC; Lane JA; Mason M; Metcalfe C; Walsh E; Blazeby JM; Peters TJ; Holding P; Bonnington S; Lennon T; Bradshaw L; Cooper D; Herbert P; Howson J; Jones A; Lyons N; Salter E; Thompson P; Tidball S; Blaikie J; Gray C; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Davis M; Turner EL; Martin RM; Neal DE;
    N Engl J Med; 2016 Oct; 375(15):1425-1437. PubMed ID: 27626365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer.
    Eccles BK; Cross W; Rosario DJ; Doble A; Parker C; Logue J; Little L; Stanton L; Bottomley D
    BJU Int; 2013 Aug; 112(3):330-7. PubMed ID: 23826842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
    Bárcena PGQ; Aprikian AG; Dragomir A
    Cancer Med; 2024 Feb; 13(3):e6922. PubMed ID: 38351647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.
    Sooriakumaran P; Wilson C; Rombach I; Hassanali N; Aning J; D Lamb A; Cathcart P; Eden C; Ahmad I; Rajan P; Sridhar A; Bryant RJ; Elhage O; Cook J; Leung H; Soomro N; Kelly J; Nathan S; Donovan JL; Hamdy FC
    BJU Int; 2022 Jul; 130(1):43-53. PubMed ID: 34878715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial of robotic and open prostatectomy in men with localised prostate cancer.
    Gardiner RA; Yaxley J; Coughlin G; Dunglison N; Occhipinti S; Younie S; Carter R; Williams S; Medcraft RJ; Bennett N; Lavin MF; Chambers SK
    BMC Cancer; 2012 May; 12():189. PubMed ID: 22632109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and functional outcomes for risk-appropriate treatments for prostate cancer.
    Tiruye T; O'Callaghan M; Ettridge K; Moretti K; Jay A; Higgs B; Santoro K; Kichenadasse G; Beckmann K
    BJUI Compass; 2024 Jan; 5(1):109-120. PubMed ID: 38179028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection.
    Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
    Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer.
    Lonergan PE; Baskin A; Greenberg SA; Mohamad O; Washington SL; Zhao S; Cowan JE; Broering JM; Nguyen HG; Cooperberg MR; Breyer BN; Carroll PR
    Urology; 2023 Aug; 178():114-119. PubMed ID: 37244430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
    BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between age and long-term quality of life after curative treatment for prostate cancer: a cross-sectional study.
    Sletten R; Berger Christiansen O; Oldervoll LM; Åstrøm L; Kjesbu Skjellegrind H; Šaltytė Benth J; Kirkevold Ø; Bergh S; Grønberg BH; Rostoft S; Bye A; Mork PJ; Slaaen M
    Scand J Urol; 2024 Feb; 59():31-38. PubMed ID: 38379397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.
    Wade J; Donovan J; Lane A; Davis M; Walsh E; Neal D; Turner E; Martin R; Metcalfe C; Peters T; Hamdy F; Kockelbergh R; Catto J; Paul A; Holding P; Rosario D; Kynaston H; Rowe E; Hughes O; Bollina P; Gillatt D; Doherty A; Gnanapragasam VJ; Paez E
    BMJ Open; 2020 Sep; 10(9):e036024. PubMed ID: 32907896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
    Donovan JL; Hamdy FC; Lane JA; Young GJ; Metcalfe C; Walsh EI; Davis M; Steuart-Feilding T; Blazeby JM; Avery KNL; Martin RM; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Wade J; Turner EL; Williams NJ; Oxley J; Staffurth J; Bryant RJ; Neal DE
    NEJM Evid; 2023 Apr; 2(4):EVIDoa2300018. PubMed ID: 38320051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.